2018
Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States
Ramalingam S, Dinan MA, Crawford J. Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States. Journal Of Thoracic Oncology 2018, 13: 1842-1850. PMID: 30312680, DOI: 10.1016/j.jtho.2018.09.007.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdenocarcinoma of LungAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCommunity Health CentersFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective StudiesSurvival RateUnited StatesConceptsCommunity-based centersNational Cancer DatabaseSquamous cell carcinomaAcademic centersMetastatic NSCLCCell carcinomaLung cancerCancer DatabaseStage IV lung cancerSquamous cell lung cancerStage IV NSCLCPercentage of patientsYear of diagnosisCell lung cancerVariety of chemotherapyMultivariable regression modelsPrimary outcomeHistologic typeMultivariable analysisSignificant relative increasePrimary payerSurvival differencesSurvival comparisonsMultivariable modelTreatment strategies
2015
Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 1529-1536. PMID: 25642591, PMCID: PMC4399282, DOI: 10.1210/jc.2014-4332.Peer-Reviewed Original ResearchConceptsRadioactive iodine therapyPapillary thyroid cancerIntermediate-risk papillary thyroid cancerAdjuvant radioactive iodine therapyIntermediate-risk PTC patientsImproved overall survivalIntermediate-risk patientsOverall survivalRisk of deathRAI therapyIodine therapyPTC patientsThyroid cancerAmerican Thyroid Association riskLong-term prognosisAmerican Joint CommissionCommon endocrine malignancyPaucity of dataTotal thyroidectomyAdult patientsMultivariate adjustmentClinical factorsAggressive variantStage T3Patient group
2014
Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival
Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA. Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival. Annals Of Surgery 2014, 260: 601-607. PMID: 25203876, PMCID: PMC4532384, DOI: 10.1097/sla.0000000000000925.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerExtent of surgeryTotal thyroidectomyOverall survivalTumor sizeDistant metastasisThyroid cancerSurvival advantagePTC tumorsRadioactive iodine treatmentLarge contemporary cohortOverall survival advantageUnderwent total thyroidectomyProportional hazards modelPresence of nodalMultivariable adjustmentAdult patientsClinical factorsContemporary cohortMultifocal diseaseAbsolute indicationMale sexTumors 1.0Black racePTC patientsTreatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States
Gratian L, Pura J, Dinan M, Reed S, Scheri R, Roman S, Sosa JA. Treatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States. Annals Of Surgical Oncology 2014, 21: 3509-3514. PMID: 25069860, PMCID: PMC4515350, DOI: 10.1245/s10434-014-3931-z.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultAgedDatabases, FactualElective Surgical ProceduresFemaleFollow-Up StudiesHospitals, High-VolumeHospitals, Low-VolumeHumansLength of StayMaleMiddle AgedNeoplasm StagingOutcome and Process Assessment, Health CarePractice Patterns, Physicians'RegistriesReoperationSurvival RateWorkloadConceptsHigh-volume centersLow-volume centersHospital case volumeOverall survivalTreatment patternsCase volumeRegional lymph node evaluationAggressive surgical resectionLymph node evaluationPrimary adrenal malignancyMedian overall survivalNational Cancer DatabasePostoperative mortality rateBackgroundAdrenocortical carcinomaChemotherapy useAggressive treatmentRadical resectionReadmission ratesSurgical resectionAdrenal malignancyCarcinoma AssociatedClinical outcomesTumor characteristicsACC patientsAggressive diseaseRobotic Thyroidectomy for Cancer in the US: Patterns of Use and Short-Term Outcomes
Abdelgadir Adam M, Speicher P, Pura J, Dinan MA, Reed SD, Roman SA, Sosa JA. Robotic Thyroidectomy for Cancer in the US: Patterns of Use and Short-Term Outcomes. Annals Of Surgical Oncology 2014, 21: 3859-3864. PMID: 24934584, PMCID: PMC4519825, DOI: 10.1245/s10434-014-3838-8.Peer-Reviewed Original ResearchConceptsShort-term outcomesRobotic thyroidectomyMultivariable analysisOpen thyroidectomyOpen surgeryThyroid cancerPatterns of useRobotic casesRobotic groupRobotic surgeryThyroidectomy-specific complicationsUnderwent open surgeryNational Cancer DatabaseLong-term outcomesLength of stayMulti-institutional studyNon-significant increaseMore Asian patientsTotal thyroidectomyUnderwent lobectomyUnderwent thyroidectomyLymph nodesSurgery useAsian patientsPositive marginsImpact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United States
Gratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA. Impact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United States. Annals Of Surgical Oncology 2014, 21: 3515-3521. PMID: 24841347, PMCID: PMC4510956, DOI: 10.1245/s10434-014-3769-4.Peer-Reviewed Original ResearchConceptsNonfunctional pancreatic neuroendocrine tumorsPancreatic neuroendocrine tumorsExtent of surgerySmall Nonfunctional Pancreatic Neuroendocrine TumorsFive-year OSOverall survivalMalignant potentialNeuroendocrine tumorsNational Cancer Data BaseLymph node dissectionLymph node resectionKaplan-Meier analysisType of surgeryLog-rank testUncertain malignant potentialImpact of extentNode dissectionNode resectionTotal pancreatectomyPatient characteristicsRegional lymphRegional lymphadenectomySurgical resectionImproved survivalDistant metastasisRedistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005. Journal Of Thoracic Oncology 2014, 9: 512-518. PMID: 24736074, DOI: 10.1097/jto.0000000000000102.Peer-Reviewed Original ResearchConceptsCell lung cancerTotal health care costsHealth care costsPositron emission tomographyProportion of patientsRate of surgeryMedicare beneficiariesLung cancerCare costsEmission tomographySurgical resectionInpatient costsRetrospective cohort studyYear of diagnosisMain outcome measuresCohort studyTreatment patternsOutcome measuresRadiation therapyChemotherapyPatientsRadiotherapyStudy periodCancerMedicare approval